Revance Therapeutics Inc (NASDAQ:RVNC)
| 28.63 Delayed Data As of Jan 22 |  +0.24 / +0.85%Today’s Change | 11.78 Today|||52-Week Range 34.62 | +1.02% Year-to-Date |
Latest RVNC News | Press Releases
No recent news for Revance Therapeutics Inc.
Today’s Trading
| Previous close | 28.39 |
| Today’s open | 27.91 |
| Day’s range | 27.91 - 28.83 |
| Volume | 18,989 |
| Average volume (3 months) | 578,358 |
| Market cap | $1.9B |
Data as of 3:59pm ET, 01/22/2021
Growth & Valuation
| Earnings growth (last year) | +6.93% |
| Earnings growth (this year) | -33.44% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -88.92% |
| P/E ratio | NM |
| Price/Sales | 1,707.91 |
| Price/Book | 6.65 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PBHPrestige Consumer He... | +0.14 | +0.37% |
| VCELVericel Corp | +1.09 | +2.71% |
| ---- | ||
| YMABY-mAbs Therapeutics,... | -0.07 | -0.16% |
Data as of 4:00pm ET, 01/22/2021
Financials
| Next reporting date | March 3, 2021 |
| EPS forecast (this quarter) | -$1.18 |
| Annual revenue (last year) | $413.0K |
| Annual profit (last year) | -$159.4M |
| Net profit margin | -38,602.66% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Nashville, Tennessee |
Forecasts
